Global Immune Check Activators Competitive Landscape, Technology and Pipeline Analysis, 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Immune Check Activators- Competitive Landscape, Technology and Pipeline Analysis, 2016" report to their offering.

This report deals with the TNFR/TNF superfamily members as agents of Cancer Immunotherapy that have brought a new dawn upon the existing therapies for cancer. Controlling diverse facets of immune function, it has brought into application a technology that rested in the pipeline for years. In the present scenario, members of the TNFR/TNF superfamily are being targeted to maintain, modulate and regulate body's own immune system to fight cancer.

The rationale of this therapy is to mitigate/ avoid side effects, resistance, toxicity and pain brought by the combination therapy of surgery, radiation and chemotherapy. The future of this therapy lies strong as will be seen before 2020 as majority of its products will show results on safety, efficacy and dosing as they move to their Phase II trials in the provided timeline.

Report Highlights

- Immune Checkpoint Activators Therapy Pipeline scenario

- Collaborations & partnering deals

- Current Prominent Research Areas and Key Players

- Pipeline product profiles Immune Checkpoint Activators Technologies and Targeted Antigens

- Licensing opportunities

- Market Drivers and Barriers

Key Topics Covered:

1 Executive Summary

2 Executive Summary Snapshot

3 Immune checkpoints Activator Overview

4 ImmuneCheck Activators Analysis

5 Market Drivers

6 Market Barriers

7 Pipeline Therapeutics

8 Late Stage Products (Phase III)

9 Mid Stage Products (Phase II)

10 Early Stage Products (Phase I and IND)

11 Pre-Clinical and Discovery Products

12 Therapeutic Assessment

Companies Mentioned

- GlaxoSmithKline Pharmaceuticals

- Pfizer

- Genentech

- Five Prime Therapeutics

- Inhibrx

- Agenus

- Incyte Corporation

- Leap Therapeutics

- Agenus

- Apexigen

- Kymab

- Pfizer

- Genentech

- MedImmune LLC

For more information visit http://www.researchandmarkets.com/research/9qxz83/immune_check

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs